Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments

被引:8
|
作者
Katic, Alain
Dirks, Bryan [1 ]
Babcock, Thomas [2 ]
Scheckner, Brian [2 ]
Adeyi, Ben [3 ]
Richards, Cynthia [1 ]
Findling, Robert L. [4 ]
机构
[1] Shire Dev LLC, Clin Dev & Innovat, Wayne, PA USA
[2] Shire Dev LLC, Global Med Affairs, Wayne, PA USA
[3] Shire Dev LLC, Biostat & Stat Programming Dept, Wayne, PA USA
[4] Johns Hopkins Univ, Johns Hopkins Med & Kennedy Krieger Inst, Div Child & Adolescent Psychiat, Baltimore, MD USA
关键词
DEFICIT HYPERACTIVITY; EXPRESSION;
D O I
10.1089/cap.2012.0104
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: The purpose of this study was to assess lisdexamfetamine dimesylate (LDX) treatment effects based on baseline emotional control dysfunction in children with attention-deficit/hyperactivity disorder (ADHD) categorized with or without impairments of executive function (EF) emotional control. Methods: Post-hoc analyses of a 7 week, open-label LDX study in children with ADHD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision [DSM-IV-TR] defined) and impairments in EF control of emotional response. At baseline, participants were dichotomized by Behavior Rating Inventory of EF (BRIEF) emotional control domain T-scores of >= 65 (with impairment) or <65 (without impairment). ADHD Rating Scale-IV (ADHD-RS-IV), BRIEF Global Executive Composite and emotional control domain, Expression and Emotion Scale for Children (EESC) scores, Pearson correlations for BRIEF versus ADHD-RS-IV and EESC, and Clinical Global Impressions scores were assessed at baseline and end of study (week 7)/early termination (EOS/ET) by baseline category of BRIEF emotional control impairment. Safety assessments included treatment-emergent adverse events (TEAEs). Results: At baseline and EOS/ET, respectively, 53.0% and 20.7% met criteria for emotional control impairment. Participants with and without emotional control impairments had similar ADHD-RS-IV change scores. Mean (SD) change from baseline for those with and without emotional control impairments were -20.8 (12.89) and -14.6 (11.25) for BRIEF global scores and -16.0 (13.19) and -5.0 (9.48) for BRIEF emotional control domain scores. Participants with emotional control impairments had greater mean EESC total score changes. BRIEF emotional control domain and all ADHD-RS-IV scores indicated moderate correlations between change scores (all p < 0.0001). Overall, 84.9% of participants had TEAEs (mostly mild-to-moderate in severity); 3.8% discontinued because of TEAEs. Conclusions: The proportion of children with behavioral impairments in EF control of emotional response decreased during LDX treatment. ADHD symptoms improved in both groups. The moderate correlations between EF behaviors and ADHD symptoms suggest there may be utility in evaluating behavioral domains beyond core ADHD symptoms.
引用
收藏
页码:386 / 393
页数:8
相关论文
共 50 条
  • [31] Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
    Zuddas, A.
    Banaschewski, T.
    Nagy, P.
    Soutullo, C.
    Yan, B.
    Caballero, B.
    Coghill, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S648 - S648
  • [32] A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
    Zimovetz, Evelina A.
    Joseph, Alain
    Ayyagari, Rajeev
    Mauskopf, Josephine A.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (01): : 21 - 35
  • [33] A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
    Evelina A. Zimovetz
    Alain Joseph
    Rajeev Ayyagari
    Josephine A. Mauskopf
    The European Journal of Health Economics, 2018, 19 : 21 - 35
  • [34] Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: A post hoc analysis
    Jain R.
    Babcock T.
    Burtea T.
    Dirks B.
    Adeyi B.
    Scheckner B.
    Lasser R.
    Child and Adolescent Psychiatry and Mental Health, 5 (1)
  • [35] Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe
    Haege, A.
    Banaschewski, T.
    Dittmann, R. W.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2015, 83 (12) : 676 - 685
  • [36] Sex Subgroup Analysis of Treatment Response to Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder
    McGough, James J.
    Greenbaum, Michael
    Adeyi, Ben
    Babcock, Thomas
    Scheckner, Brian
    Dirks, Bryan
    Findling, Robert L.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (01) : 138 - 140
  • [37] Long-term safety of lisdexamfetamine dimesylate (LDX) in adolescents with attention-deficit/hyperactivity disorder
    Findling, R.
    Childress, A.
    Cutler, A.
    Hamdani, M.
    Ferreira-Cornwell, M. C.
    Shaw, M.
    Gasior, M.
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2011, 20 (01) : S117 - S118
  • [38] The Efficacy and Safety Profile of Lisdexamfetamine Dimesylate, a Prodrug of d-Amphetamine, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adults
    Najib, Jadwiga
    CLINICAL THERAPEUTICS, 2009, 31 (01) : 142 - 176
  • [39] Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
    Weisler, Richard
    Young, Joel
    Mattingly, Greg
    Gao, Joseph
    Squires, Liza
    Adler, Lenard
    CNS SPECTRUMS, 2009, 14 (10) : 573 - 585
  • [40] Maintenance of Efficacy of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder: Randomized Withdrawal Design
    Brams, Matthew
    Weisler, Richard
    Findling, Robert L.
    Gasior, Maria
    Hamdani, Mohamed
    Ferreira-Cornwell, M. Celeste
    Squires, Liza
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (07) : 977 - 983